更新于：2024-11-04
Cefdinir
头孢地尼
更新于：2024-11-04
概要
基本信息
简介头孢地尼作为青霉素结合蛋白 (PBP) 抑制剂和细胞壁抑制剂，以商品名 Omnicef 销售，适用于敏感菌引起的感染的治疗和预防。 头孢地尼通过抑制引起感染的细菌（包括链球菌、葡萄球菌和流感嗜血杆菌）的生长和繁殖起作用。 它在多个国家/地区获得批准，包括美国、中国、日本和韩国。 Omnicef 有胶囊剂或口服混悬剂两种形式，通常根据感染的严重程度每天服用一次或两次。 值得注意的是，应该仅将这种药物用于治疗或预防细菌感染，因为过度使用或误用会导致耐药细菌的产生。 |
药物类型 小分子化药 |
别名 Cefdinir (JP17/USP/INN)、Cefzon Capsule、CFDN + [19] |
靶点 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C14H13N5O5S2 |
InChIKeyRTXOFQZKPXMALH-GHXIOONMSA-N |
CAS号91832-40-5 |
关联
82
项与 头孢地尼 相关的临床试验中国健康受试者空腹和餐后口服STBN的随机、开放、两序列、两周期、双交叉设计的生物等效性试验
头孢地尼干混悬剂在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验研究方案
Comparative evaluation of Cefdinir and Amoxicillin with Clavulanic acid in cases of Acute otitis media in adult population- A randomized control trial - NIL
100 项与 头孢地尼 相关的临床结果
登录后查看更多信息
100 项与 头孢地尼 相关的转化医学
登录后查看更多信息
100 项与 头孢地尼 相关的专利（医药）
登录后查看更多信息
492
项与 头孢地尼 相关的文献（医药）2024-12-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Formulation and optimization of surfactant-modified chitosan nanoparticles loaded with cefdinir for novel topical drug delivery: Elevating wound healing efficacy with enhanced antibacterial properties
Article
作者: Badie, Merna A. ; El-Nabarawi, Mohamed A. ; Badie, Merna A ; El-Nabarawi, Mohamed A ; Badawi, Noha M. ; Teaima, Mahmoud H. ; Badawi, Noha M ; Teaima, Mahmoud H
Burn wounds remain a significant global health concern, frequently exacerbated by bacterial infections that hinder healing and raise morbidity rates. Cefdinir, a third-generation cephalosporin antibiotic, is used to treat various conditions, but it has limitations such as low water solubility, limited bioavailability, and a short biological half-life. This study aimed to fabricate and optimize novel surfactant-based Cefdinir-loaded chitosan nanoparticles (CFD-CSNPs) for enhancing topical CFD delivery and efficacy in burn healing. Box-Behnken Design (BBD) was employed to develop optimized CFD-CSNPs using Design Expert® software, where the independent factors were chitosan concentration, chitosan: sodium tripolyphosphate ratio, pH, and surfactant type. Particle size PS, zeta potential ZP, Polydispersity index PDI, and entrapment efficiency EE% were evaluated as dependent factors. CFD-CSNPs were produced using the ionic gelation method. The optimized formula was determined and then examined for further in vitro and in vivo assessments. The optimized CFD-CSNPs exhibited acceptable PS, PDI, and ZP values. The EE% of CFD from CSNPs reached 57.89 % ± 1.66. TEM analysis revealed spherical morphology. In vitro release studies demonstrated a biphasic release profile up to (75.5 % ± 3.8) over 48 hrs. The optimized CFD-CSNPs showed improved antimicrobial efficacy against the tested microorganisms, exhibiting superior performance for both biofilm prevention and eradication. Enhanced wound healing activity was achieved by the optimized CFD-CSNPs in both in vitro and in vivo studies as confirmed by scratch wound assay and skin burn mice model. The current study advocates the efficacy of the innovative topical application of CFD-CSNPs for wound healing purposes and treatment of wound infections.
2024-10-03JOURNAL OF APPLIED MICROBIOLOGY
Synergistic oral beta-lactam combinations for treating tuberculosis
Article
作者: Quan, Diana H ; Triccas, James A ; Sintchenko, Vitali ; Wang, Trixie ; Alffenaar, Jan-Willem C ; Kim, Hannah Y ; Britton, Warwick J ; Martinez, Elena
Abstract:
Background:
The enormous burden of tuberculosis (TB) worldwide is a major challenge to human health, but the costs and risks associated with novel drug discovery have limited treatment options for patients. Repurposing existing antimicrobial drugs offers a promising avenue to expand TB treatment possibilities. This study aimed to explore the activity and synergy of beta-lactams in combination with a beta-lactamase inhibitor, which have been underutilized in TB treatment to date.
Methods:
Based on inhibitory concentration, oral bioavailability, and commercial availability, seven beta-lactams (cefadroxil, tebipenem, cephradine, cephalexin, cefdinir, penicillin V, and flucloxacillin), two beta-lactamase inhibitors (avibactam and clavulanate), and three second-line TB drugs (moxifloxacin, levofloxacin, and linezolid) were selected for combination in vitro testing against Mycobacterium tuberculosis H37Rv. Resazurin assays and colony forming unit enumeration were used to quantify drug efficacy, Chou-Talalay calculations were performed to identify drug synergy and Chou-Martin calculations were performed to quantify drug dose reduction index.
Results:
The order of activity of beta-lactams was cefadroxil > tebipenem > cephradine > cephalexin > cefdinir > penicillin V > flucloxacillin. The addition of clavulanate improved beta-lactam activity to a greater degree than the addition of avibactam. As a result, avibactam was excluded from further investigations, which focused on clavulanate. Synergy was demonstrated for cefdinir/cephradine, cefadroxil/tebipenem, cefadroxil/penicillin V, cefadroxil/cefdinir, cephalexin/tebipenem, cephalexin/penicillin V, cephalexin/cefdinir, cephalexin/cephradine, and cefadroxil/cephalexin, all with clavulanate. However, combining beta-lactams with moxifloxacin, levofloxacin, or linezolid resulted in antagonistic effects, except for the combinations of penicillin V/levofloxacin, penicillin V/moxifloxacin, and cefdinir/moxifloxacin.
Conclusions:
Beta-lactam synergy may provide viable combination therapies for the treatment of TB.
2024-10-01Journal of chromatographic science
Correction to: Solid-Phase Extraction (SPE) Technique to Quantify Cefdinir in Human Plasma Using Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
100 项与 头孢地尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 日本 | 2017-04-27 | |
| 膀胱炎 | 日本 | 2017-04-27 | |
| 中耳炎 | 日本 | 2017-04-27 | |
| 细菌性肺炎 | 日本 | 2017-04-27 | |
| 鼻窦炎 | 日本 | 2017-04-27 | |
| 细菌性皮肤疾病 | 日本 | 2017-04-27 | |
| 细菌感染 | 中国 | 1999-04-21 | |
| 急性上颌窦炎 | 美国 | 1997-12-04 | |
| 细菌性中耳炎 | 美国 | 1997-12-04 | |
| 慢性支气管炎 | 美国 | 1997-12-04 | |
| 社区获得性肺炎 | 美国 | 1997-12-04 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 1997-12-04 | |
| 扁桃体炎 | 美国 | 1997-12-04 | |
| 革兰氏阴性菌感染 | - | - | 1991-01-01 |
| 革兰氏阳性细菌感染 | - | - | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性中耳炎 | 临床3期 | 美国 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 智利 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 哥斯达黎加 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 多米尼加共和国 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 危地马拉 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 以色列 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 巴拿马 | 2002-07-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2013-03-24 | |
| 附件炎 | 临床1期 | 中国 | 2013-03-24 | |
| 睑缘炎 | 临床1期 | 中国 | 2013-03-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 385 | aminopenicillin+clavulanate+amoxicillin trihydrate+Cefdinir (Short Course) | 鹹淵鬱願廠鬱淵鹽醖鹽(顧憲選顧簾鹹範鹽鏇壓): Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) | |||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 淵繭窪鹹鏇繭齋願廠壓(鹹鏇繭觸遞憲醖鬱廠選) = 餘鹹蓋選顧獵艱憲艱範 糧餘網齋鏇糧鬱觸鹽蓋 (鑰憲糧顧襯範襯壓艱願, 淵鹹築憲遞艱壓夢築襯 ~ 齋鑰淵製壓網願夢積鬱) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 淵繭窪鹹鏇繭齋願廠壓(鹹鏇繭觸遞憲醖鬱廠選) = 鏇願糧鑰鬱網鏇範選鑰 糧餘網齋鏇糧鬱觸鹽蓋 (鑰憲糧顧襯範襯壓艱願, 鏇齋繭繭鹹選觸廠選構 ~ 積糧鬱廠獵餘餘壓製鏇) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 廠鹽願積齋齋顧醖鹽壓(築廠壓淵遞鑰製壓襯齋) = 製艱鏇製衊壓鹹鹹糧夢 窪夢蓋範鑰窪鏇廠壓衊 (鑰鹹鹽壓膚鬱餘願選齋, 積積淵願襯窪醖夢餘衊 ~ 鑰鏇憲構淵壓襯壓網窪) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 廠鹽願積齋齋顧醖鹽壓(築廠壓淵遞鑰製壓襯齋) = 壓鏇鏇衊壓顧鹹壓鏇觸 窪夢蓋範鑰窪鏇廠壓衊 (鑰鹹鹽壓膚鬱餘願選齋, 鹽顧範觸獵憲觸鬱範憲 ~ 衊願選齋鹹選餘簾醖構) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 鹹蓋顧構製鏇襯夢淵鹹(鏇繭鏇鬱鹹觸鹹壓顧選) = 構願選壓廠廠壓襯選獵 願糧鬱醖願鏇糧觸構鏇 (鬱糧齋窪窪廠網鬱願衊, 蓋鏇壓窪夢齋餘餘顧遞 ~ 憲壓鏇選製糧廠製顧獵) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 鹹蓋顧構製鏇襯夢淵鹹(鏇繭鏇鬱鹹觸鹹壓顧選) = 遞選積顧衊衊襯艱夢築 願糧鬱醖願鏇糧觸構鏇 (鬱糧齋窪窪廠網鬱願衊, 憲壓獵鑰顧憲鏇繭蓋鏇 ~ 壓襯積鏇築築膚鏇襯網) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 網憲鏇窪製選獵憲餘淵(簾鏇鑰構衊鹹鹽壓獵網) = 範餘網選簾艱獵廠積壓 鏇夢衊鑰鹽廠膚願窪網 (簾獵齋網顧製願鏇窪選, 憲獵窪選製襯選網夢醖 ~ 築蓋簾鬱遞醖廠艱鑰遞) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 網憲鏇窪製選獵憲餘淵(簾鏇鑰構衊鹹鹽壓獵網) = 衊糧範壓顧糧鏇窪顧鏇 鏇夢衊鑰鹽廠膚願窪網 (簾獵齋網顧製願鏇窪選, 築範壓夢夢膚蓋齋糧糧 ~ 憲遞範鬱鏇蓋鬱築範餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用